健民集团(600976) - 2017 Q1 - 季度财报

Financial Performance - Operating revenue for the period was CNY 579,991,133.04, representing a decline of 7.71% year-on-year[6] - Net profit attributable to shareholders was CNY 15,882,709.42, down 28.42% from the previous year[6] - Basic earnings per share decreased by 20% to CNY 0.12[6] - The company reported a significant increase in operating income, with a notable rise in non-operating income by 194.70% to RMB 113,092.90[14] - Total operating revenue for Q1 2017 was CNY 579,991,133.04, a decrease of 7.7% compared to CNY 628,440,869.93 in the same period last year[24] - Net profit for Q1 2017 was CNY 18,104,328.96, a decline of 21.5% from CNY 23,092,839.98 in Q1 2016[25] - The total comprehensive income attributable to the parent company was CNY 17,700,964.16, compared to CNY 23,076,328.02 in the previous year, reflecting a significant decrease[26] - The net profit for Q1 2017 was CNY 13,316,447.05, a decrease of 8.7% from CNY 14,577,257.69 in Q1 2016[29] - Operating profit for Q1 2017 was CNY 14,631,775.76, a decline of 5.0% from CNY 16,461,855.52 in the previous year[28] Cash Flow - Cash flow from operating activities showed a significant decline, with a net cash outflow of CNY 84,167,612.68, a decrease of 640.93% compared to the same period last year[6] - Cash flow from operating activities for Q1 2017 was negative at CNY -84,167,612.68, worsening from CNY -11,359,773.91 in Q1 2016[32] - The company incurred a total of CNY 679,561,626.19 in cash outflows from operating activities, compared to CNY 758,860,702.87 in the previous year[32] - The net cash flow from operating activities was -7,787,894.24 RMB, a significant decrease compared to 27,445,170.47 RMB in the previous period, indicating a decline in operational efficiency[34] - Cash inflow from investment activities totaled 407,566,281.25 RMB, down from 529,793,340.04 RMB in the prior period, reflecting a reduction in investment returns[35] - The cash outflow for investment activities was 357,307,844.57 RMB, compared to 269,853,924.84 RMB previously, showing an increase in investment expenditures[35] - The total cash and cash equivalents at the end of the period stood at 195,163,432.79 RMB, down from 304,082,956.53 RMB previously, reflecting a decline in liquidity[35] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,807,092,480.70, a decrease of 0.04% compared to the end of the previous year[6] - Current liabilities totaled RMB 739,168,387.32, a decrease from RMB 759,077,449.25 at the beginning of the year[17] - Total liabilities as of March 31, 2017, were CNY 256,084,804.11, slightly up from CNY 253,504,909.89 at the start of the year[22] - The company's total assets as of March 31, 2017, amounted to CNY 1,254,962,428.09, an increase from CNY 1,239,066,086.82 at the beginning of the year[22] - The company's total equity as of March 31, 2017, was CNY 998,877,623.98, up from CNY 985,561,176.93 at the beginning of the year, marking a growth of 1.3%[22] Shareholder Information - The number of shareholders at the end of the reporting period was 9,164[11] - The largest shareholder, Huafang Pharmaceutical Technology Co., Ltd., held 22.07% of the shares[11] Expenses - Sales expenses increased by 31.15% to RMB 109,465,831.08 due to increased marketing investments[14] - Cash paid for purchasing goods and services was 33,731,920.31 RMB, up from 25,844,331.56 RMB, suggesting increased operational costs[34] - Cash paid to employees increased to 40,647,299.72 RMB from 27,675,469.47 RMB, reflecting higher labor costs[34] Other Financial Metrics - The weighted average return on equity fell by 25.75 percentage points to 1.73%[6] - The company reported an investment income of CNY 8,562,837.32 for Q1 2017, an increase from CNY 6,744,009.15 in the previous year[25] - Other receivables decreased by 43.52% to RMB 23,706,939.21 due to the recovery of guarantee deposits[13] - Long-term deferred expenses increased by 151.71% to RMB 1,741,491.38 primarily due to new expenses related to the renovation of the Wuhan cultural headquarters[13] - Short-term borrowings surged by 261.23% to RMB 34,930,121.20 mainly due to new short-term loans from Wuhan Jianmin Zhongwei Pharmaceutical Co., Ltd.[13] - Prepayments decreased by 71.58% to RMB 9,260,979.11 as revenue was recognized from previously received customer payments[13]